Optimizing Paediatric and Adolescent ART: Challenges and Opportunities
|
|
- Melanie Mills
- 5 years ago
- Views:
Transcription
1 Optimizing Paediatric and Adolescent ART: Challenges and Opportunities Dr Nandita Sugandhi ICAP at Columbia University PATA 2017 Continental Summit 24 October, 2017 Johannesburg South Africa
2 Overview What are our current challenges in ART for children and adolescents? What is optimization of ART for children and adolescent and what does it look like today? What is ahead for the optimization of ART for children and adolescents?
3 Overview What are our current challenges in ART for children and adolescents? What is optimization of ART for children and adolescent and what does it look like today? What is ahead for the optimization of ART for children and adolescents?
4 72% of all people living with HIV will know their HIV status of all people diagnosed with HIV will receive ARVs of all people receiving ARVs will be virally suppressed of all people living with HIV will be virally suppressed
5 We have committed to SUPER FAST TRACK TARGETS! AIDS Free: Provide 1.6 million children (aged 0 14) living with HIV with lifelong antiretroviral therapy by [Reach 95% of all children living with HIV]
6 Paediatric HIV Care and Treatment Trends Birth testing and EID Growing adolescent population
7 Courtesy of Prof. E.M. Obimbo, University of Nairobi
8 Initiating paediatric ART since 2013 Preferred Alternative Children < 3 years ABC + 3TC + LPV/r or AZT + 3TC + LPV/r ABC + 3TC + NVP AZT + 3TC + NVP Children 3 years to < 10 years ABC + 3TC + EFV ABC + 3TC + NVP AZT + 3TC + EFV AZT + 3TC + NVP TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + NVP LPV/r a preferred drug for ALL infants and children <3 yrs AZT/3TC/NVP is suboptimal but included as an alternative option
9 LPV/r for 1 st line in < 3 years Age group Kaletra syrup Requires cold chain Bitter taste Toxic excipients Heavy to carry Hard to store Preferred 1 st Line <3 years ABC or AZT + 3TC + LPV/r
10 ABC + 3TC + EFV: Preferred for children 3-10 yrs Preferred Children 3 years to < 10 years ABC + 3TC + EFV Alternative ABC + 3TC + NVP AZT + 3TC + EFV AZT + 3TC + NVP TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + NVP ABC/3TC ABC/3TC Tab (disp, scored) 60/30mg Tab (disp, scored) 120/60mg 3-5.9kg 6-9.9kg kg kg kg EFV Tab (scored) Multiple tablets needed to provide a complete 3 drug regimen
11 % of children on 1st L. ART Main First line paediatric ART regimens among children 0-15 years old end 2015 in LMICs (n=748,638) % of all children in LMIC were still on AZT/3TC/NVP at the end of WHO ARV use survey in 2016
12 Adolescents: Harmonized with Adults First-line ART Adults Adolescents Preferred first-line regimens TDF + XTC + EFV TDF + XTC + EFV Alternative first-line regimens AZT + 3TC + EFV (or NVP) TDF + XTC + DTG TDF + XTC + EFV 400 TDF + XTC + NVP AZT + 3TC + EFV (or NVP) TDF (or ABC) + XTC + DTG TDF (or ABC) + XTC + EFV 400 TDF (or ABC) + XTC + NVP
13 Is this the best we can do?
14 Population-level HIV incidence assessments
15 ACTION QUALITY TRENDS Increasing levels of HIV Drug Resistance A systematic literature review of pretreatment drug resistance in children documented high rates of resistance in children starting ART, particularly those that had been exposed to NNRTI s during PMTCT In South Africa, one study showed that 63.7% of infants and children <18 months had HIVDR NNRTI resistance: 62.7% NRTI resistance: 13.9% At the end of 2015 only 14% of children 0-15 years across 66 LMIC were on boosted PI-based regimens HIV DRUGRESISTANCE REPORT
16 Many reasons for lack of LPVr uptake in young children but NNRTI resistance is rising 100% 80% 60% 79% 72% Zimbabwe Swaziland In young infants HIVDR levels are very high 40% 44% 48% Most of this is NNRTI resistance ~40% Y181 20% 22% 25% 23% 13% Even children who are not exposed to PMTCT had high levels 0% 0-3 months 4-6 months 7-12 months months Source: WHO 2011 HIV DR surveys in PCR positive infants
17 Viral resistance in sexually active youth with HIV RNA>5000 copies/ml (n=38) Slide courtesy of Theodore Ruel 42% of 92 sexually active 1 VL >5000 copies/ml 81 % had resistance to 1 ARV class 24% had some resistance to drugs in all 3 classes 63% with resistance reported unprotected sex Tassiopoulos, CID, 2013.
18 Overview What are our current challenges in ART for children and adolescents? What is optimization of ART for children and adolescent and what does it look like today? What is ahead for the optimization of ART for children and adolescents?
19 What is ART Optimization? Potent Low toxicity Well tolerated and easy to take/administer High generic barrier to resistance/durable Improve sequencing/switching options Can be harmonized across special populations Reduce cost
20 There are options for neonates diagnosed in the 1 st month of life Dealing with limited options for newborns Optimizing options with the best formulation available Monitoring closely and adjusting dosing 0-2 weeks 2 weeks - 3 months 3 36 months Preferred Alternative Special circumstances AZT + 3TC + NVP AZT + 3TC + NVP* AZT + 3TC + NVP ABC or AZT + 3TC + LPV/r syrup ABC or AZT + 3TC + LPV/r pellets ABC or AZT + 3TC + LPV/r pellets ABC or AZT + 3TC + RAL (from 4 weeks)
21 LPV/r 40mg/10mg oral pellets LPV/r oral pellets tentatively approved by USFDA Safety and acceptability established in infants 6 months, limited evidence in infants 3-6 months of age Field evaluation is ongoing to determine if very young infants are able swallow pellets LPV/r oral pellets may provide a better alternative to deliver the preferred 1 st line ART regimen for infants and young children <3 years.
22 Offering better options for 2 nd line Children including adolescents LPV/r-based first line Younger than 3 years NNRTI-based firstline regimen First-line ART regimen Second-line ART regimen ABC + 3TC + LPV/r AZT or ABC + 3TC + AZT + 3TC + LPV/r RAL 3 years and older ABC + 3TC + LPV/r AZT + 3TC + EFV or RAL AZT + 3TC + LPV/r ABC or TDF + 3TC + EFV or RAL All ages ABC + 3TC + EFV (or NVP) AZT + 3TC + ATV/r or TDF + 3TC + EFV (or NVP) LPV/r AZT + 3TC + EFV (or NVP) ABC or TDF + 3TC + ATV/r or LPV/r Introducing more potent options for children failing on LPVr Promoting use of once daily bpi such as ATV Alternatives for adults and adolescents include DRV/r or LPV/r + RAL
23 Raltegravir (RAL) Twice daily integrase inhibitor We have dosing and approval down to 4 weeks We have pediatric formulations (chewable tab) for >10kg but powder for suspension for <10kg Low genetic barrier as compare to DTG Currently limited availability Limited interest for adults Weight band (kg) RAL Dose using chewable tablet 3 to <6 25mg BID* 6 to <10 50mg BID* 10 to < 14 75mg BID (consistent with USPI) 14 to < mg BID (consistent with USPI) 20 to < mg BID (consistent with USPI) * Chewable tablets currently only approved for children 2 yrs and 10kg
24 BREATHER ( PENTA 16) Non-inferiority randomized trial of 199 children aged 8-24 years who were suppressed (viral load < 50 c/ml for > 12 months) and receiving EFV plus two NRTIs. RESULTS at 48 weeks: 6 (short cycle) vs 7 (continuous) had a confirmed VL > 50 copies/ml [difference -1.2%, 90% confidence interval (CI) - 7.3% to 4.9%]. no evidence of increased inflammation in the SCT arm. Participants expressed a strong preference for SCT in a qualitative substudy and pre/post-trial questionnaires Slide courtesy of Theodore Ruel Butler, et al. Health Technol Assess, 2016.
25 Adolescents: Harmonized with Adults First-line ART Adults Adolescents Preferred first-line regimens TDF + XTC + EFV TDF + XTC + EFV Alternative first-line regimens AZT + 3TC + EFV (or NVP) TDF + XTC + DTG TDF + XTC + EFV 400 TDF + XTC + NVP AZT + 3TC + EFV (or NVP) TDF (or ABC) + XTC + DTG TDF (or ABC) + XTC + EFV 400 TDF (or ABC) + XTC + NVP
26 Adolescents: Harmonized with Adults First-line ART Adults Adolescents Preferred first-line regimens TDF + XTC + EFV TDF + XTC + EFV Alternative first-line regimens AZT + 3TC + EFV (or NVP) TDF + XTC + DTG TDF + XTC + EFV 400 TDF + XTC + NVP AZT + 3TC + EFV (or NVP) TDF (or ABC) + XTC + DTG TDF (or ABC) + XTC + EFV 400 TDF (or ABC) + XTC + NVP
27 Dolutegravir (DTG) A best in class integrase inhibitor Well tolerated Low toxicity High genetic barrier to resistance Small pill size Can be dosed twice daily in patients on TB treatment Emerging safety data on use in pregnancy Available as 50mg tab TDF/3TC/DTG 300mg/300mg/50mg (aka TLD) ABC/3TC/DTG 600mg/300mg/50mg Lower cost than currently preferred 1 st line of TDF/XTC/EFV
28 Multiple countries have already adopted dolutegravir in their guidelines Senegal Western Sahara Gambia Guinea Bissau Sierra Leone Liberia Mauritania Guinea Ivory Coast Morocco Mali Burkina Faso** Ghana Togo Algeria Benin Equatorial Guinea Niger Nigeria Tunisia Cameroon** Gabon Congo Libya Chad Angola Namibia Not pictured: Armenia, Belarus, Brazil, Cambodia, Georgia, Jamaica, Syria, Ukraine DRC Egypt** Sudan Central African Republic Rwanda Burundi Zambia Botswana South Africa Swaziland Lesotho Uganda Malawi Zimbabwe Tanzania Ethiopia Kenya Eritrea Djibouti Somalia Mozambique Madagascar Included or plan to include DTG in national guidelines Initiated procurement plan for DTG singles Botswana, Cambodia, Cote d Ivoire, DR Congo, Lesotho, Kenya, Nigeria, Uganda, South Africa, Tanzania, Zimbabwe Armenia**, Belarus**, Botswana*, Burkina Faso**, Cambodia*, Cameroon**, Cote d Ivoire*, DR Congo*, Egypt**, Georgia**, Jamaica**, Kenya*, Nigeria*, Syria**, Uganda* Ukraine**, Zimbabwe *indicates APWG country **indicates APWG country with initiated procurement plan but guidelines may not be updated DTG/TLD Adoption DTG not included in guidelines or no data DTG/TLD included in national guidelines (or confirmed plans) DTG included in national guidelines and procurement initiated 28
29 Eligibility for DTG containing regimens: Initiating Patients 2016 WHO Consolidated guidelines include DTG as an alternative WHAT to start Evidence of superiority of DTG-containing regimens for treatment-naïve patients SINGLE: DTG with ABC/3TC superior to TDF/FTC/EFV over 144 weeks with faster virologic suppression and no drug resistance FLAMINGO: DTG with 2 NRTI s superior to DRV/r with 2 NRTI s over 48 weeks SPRING 2: DTG non-inferior to RAL over a 96 week period regardless of baseline VL and NRTI back bone and Adolescents
30 Evidence for DTG use in Patients already on ART Stable First-line patients STRIIVING: non-inferiority of switch to ABC/3TC/DTG v. continuing current regimen in adults with stable viral suppression Second-line patients DAWNING: DTG superior to LPV/r when combined with 1 fully active NRTI Third-line patients SAILING: In patients with viral failure and resistance to 2 drug classes DTG superior to RAL when combined with 1-2 other fully active drugs VIIKING: In patients with viral failure and INSTI resistance, DTG BD effective when combined with 1 fully active drug.
31 DTG is still active even in heavily treatment experienced patients High suppression rates in STRIIVING regardless to genotypic susceptibility score after switching to dolutegravir-based regimen in patients with VL suppression ACTG A5353: DTG + 3TC for initial treatment of of patients with VL <500,000 DOLULAM: DTG+ 3TC maintains virological suppression even in heavily treatment experienced patients
32 Overview What are our current challenges in ART for children and adolescents? What is optimization of ART for children and adolescent and what does it look like today? What is ahead for the optimization of ART for children and adolescents?
33 There s more work to be done on optimization for children and adolescents Diagnosis Tx targets by 2018 Monitor and evaluation AIDS free Drug optimiz ation Service delivery Community engagement AIDS Free Thematic Areas Diagnosis Drug Optimization Service Delivery Community Engagement Monitoring and Evalution
34 PADO priorities ABC/3TC/EFV (Paediatric ARV Drug Optimization) DRVr & ATVr RAL FORMULATIONS of existing ARVs LPV r 4 in 1 DTG Identifying priority regimens for optimal sequencing which include newer compounds for which paediatric development has not been completed 0-3 yrs 3-10 yrs 10 yrs + NVP 20 mg FIRST LINE Mid-term (5 yr) ABC/3TC/DTG TAF/3TC/DTG New formulations of existing drugs that already have registration for children or in advanced paediatric development Long term (10 yr) TAF/3TC/DTG SECOND LINE Mid-term (5 yr) AZT/3TC/RAL or LPV/r AZT/3TC/DRV/r TAF/3TC/DRV/r Long term (10 yr) AZT/3TC/LPV/r RPV/DRV/r or AZT/3TC/DRVr
35 Dolutegravir (DTG) for younger children Low dose/kg is good for infants and children High genetic barrier ideal for poorly adherent children and adolescents OD and good toxicity profile Currently approved in 30kg and above (FDA) and 6 yrs/ 15kg (EMA) P1093 dose-finding study is ongoing Paediatric FDC planned for coformulation with abacavir and lamivudine Available in 50mg, 25mg and 10mg tablets Paediatric Dosing (EMA) Body weight (kg) Dose 15 to less than 20 20mg OD 20 to less than 30 25mg OD 30 to less than 40 35mg OD 40 or greater 50mg OD
36 ABC/3TC/EFV STR for preferred paediatric 1 st line for children >3 years Final TPP: Dispersible, scored tablet, 150/75/150 Following recent confirmation of ALE dosage, generic manufacturers have started development ABC/3TC/EFV 150mg/75mg/150mg scored dispersible tablet Weight Band 10kg kg kg kg 2 20kg kg kg - 35kg 3 # tablets daily
37 4 in 1 = 2 NRTI s + LPV/r LPV/r oral pellets tentatively approved by USFDA in 2015 but 4 in 1 still in development LIVING study- Field implementation using LPV/r pellets before availability of better-adapted 4-in-1 LPV/r based FDCs, in order to : provide better treatments to infants today and promote in-country registration & adoption provide supportive clinical data on the feasibility, effectiveness, safety, and PK of the new products in routine treatment settings The patients will switch to 4-in-1 LPV/r/AZT/3TC (40/10/30/15mg) or LPV/r/ABC/3TC (40/10/30/15mg) granules (heat stable) as soon as the products become available. A protocol amendment will be done at that time
38 Darunavir with ritonavir boosting (DRV/r) Lifelong treatment requires consideration for treatment after failure on LPV/r DRV/r can be sequenced after both LPV/r and ATV/r failure Currently no paediatric co-formulation of DRV + RTV available Priority for development Dosage form 120mg/20mg capsules for twice-daily dosing Granules may also be feasible Other potential technologies (freeze drying)
39 Tenofovir Alafenamide (TAF) Current alignment with adults on the NRTI backbone is only down to adolescents >35 kg due to concerns around TDF bone toxicity and limitations with available formulations TAF has potential for reduced toxicity and wider use than TDF Currently investigated only in 6 years and older TAF full PIP has only been planned in co-formulation, lack of single strength approval is a barrier to development of alternative promising formulations such as DTG/TAF/XTC
40 Long acting formulations a game changer? Cabotegravir and rilpivirine Phase II LATTE 1/2 look good Phase III underway in adults Antiretroviral Therapy as Long Acting Suppression (ATLAS) - switch First Long-Acting Injectable Regimen (FLAIR) - ART naïve Phase II studies for young adults in development Concern for long tail and development of resistance with nonadherence RPV detected over 500 days from last dose in 7/8 subjects * Slide courtesy of Theodore Ruel *McGovern I et al. AIDS 2016, Durban. TUAC0103
41 Conclusion Suboptimal formulations and increasing levels of drug resistance are threats to reaching the last 90 for children and adolescents Recent developments offer some improvement. This includes: LPV/r oral pellets New treatment strategies (SCT) Integrase inhibitors Raltegravir Dolutegravir But we can (and should) do better! Acknowledgements Shaffiq Essajee (UNICEF) Theodore Ruel (UCSF) Elaine Abrams (ICAP) Martina Penazzato (WHO) Dolutegravir is rapidly becoming a preferred drug for adults and adolescents
Existing and most needed paediatric ARV formulations
Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0
More informationWhat is Treatment Optimisation (TO)
Outline What is treatmen optimisation Why is treatment optimisation important for the future of HIV treatment and care Drugs optimisation Some strategies for moving the TO agend forward Discussion: Why
More informationReview of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA
Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed
More informationAIDS in Africa. An Update. Basil Reekie
AIDS in Africa An Update Basil Reekie Contents General Statistics The trend of HIV in Africa Ugandan experience UNAIDS 2006 Latest African Statistics by Country HIV Intervention Light at the end of the
More informationMANAGING HIV IN CHILDREN: BEST PRACTICES
MANAGING HIV IN CHILDREN: BEST PRACTICES Dr. Mo Archary Paediatric Infectious Diseases Specialist University of KwaZulu Natal/ King Edward VIII Hospital Overview Global state of paediatric ART Filling
More informationUpdate on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012
PMTCT Update Update on PMTCT Margarett Davis, MD, MPH Chief, Maternal and Child Health Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention (CDC) African Health Profession Regulatory
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationNew Directions on WHO ARV Guidelines 2018
New Directions on WHO ARV Guidelines 2018 Elaine Abrams Co-chair WHO Guidelines Development Group ICAP at Columbia University, New York Martina Penazzato Paediatric lead for the HIV Department World Health
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More informationART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS)
ART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS) Outline Introduction New ART molecules already adopted Dolutegravir
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationOPTIMISING FORMULATIONS Carol Ruffell. Southern African HIV Clinicians Society Conference October 2018 Skills Building Session: Infant testing
OPTIMISING FORMULATIONS Carol Ruffell Southern African HIV Clinicians Society Conference October 2018 Skills Building Session: Infant testing Background 1 Of the children living with HIV globally (most
More informationUpdate on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
More informationPROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA
5 July 2011 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-first session Yamoussoukro, Côte d Ivoire, 29 August 2 September 2011 Provisional agenda item 17.1 PROGRESS REPORT ON THE ROAD MAP FOR
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationUpdate on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges
Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato,
More informationMalaria Funding. Richard W. Steketee MACEPA, PATH. April World Malaria Day 2010, Seattle WA
Malaria Funding Richard W. Steketee MACEPA, PATH April World Malaria Day 2010, Seattle WA Malaria Funding Is there a plan? Is there money? Where does the money come from? Is the money moving efficiently?
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationUpdate on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland
Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationRationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationASLM Anti-microbial Resistance in Africa and Global Health Security. 9TH INTEREST WORKSHOP May 2015 Harare
ASLM Anti-microbial Resistance in Africa and Global Health Security 9TH INTEREST WORKSHOP 2015 8 May 2015 Harare Recent Jim O Neil Report commissioned by the UK government predicts dire consequences of
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationOverview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014
AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING Overview of 2013 WHO consolidated ARV guidelines and update plans Marco Vitoria HIV/AIDS Department WHO Geneva September 2014 AMDS ANNUAL STAKEHOLDERS AND
More informationScaling Up Nutrition Action for Africa
Scaling Up Nutrition Action for Africa Where are we and what challenges are need to be addressed to accelerate malnutrition? Lawrence Haddad Global Alliance for Improved Nutrition Why should African political
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationCurrent challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationEligibility List 2018
The Global Fund s 2017-2022 strategy and allocation-based approach enables strategic investment to accelerate the end of HIV/AIDS, tuberculosis and malaria and build resilient and sustainable systems for
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More informationASLM Building laboratory capacity in Africa in a sustainable way
ASLM Building laboratory capacity in Africa in a sustainable way Tsehaynesh Messele, PhD ASLM, Chief Executive Officer Annual AMDS meeting September 29-30, 2014 Geneva Laboratory capacity gaps in Africa
More informationForecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta
Forecasting pipeline ARVs Joseph Perriëns Sandeep Juneja Aastha Gupta Presently: lack of visibility causes a gap between demand and generic production for new drugs Patent Holder R&D Marketing 3-4 yrs
More information! Multisectoral Information, Data, Research & Evidence - for Health, Population, Human & Social Development!
Pan African Campaign To End Forced Marriage of Under Age Children Advancing Multi-sectoral Policy & Investment for Girls, Women, & Children s Health 2015 Africa Scorecard On Maternal Health & Maternal
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationAnnex 2 A. Regional profile: West Africa
Annex 2 A. Regional profile: West Africa 355 million people at risk for malaria in 215 297 million at high risk A. Parasite prevalence, 215 Funding for malaria increased from US$ 233 million to US$ 262
More informationIMMUNIZATION VACCINES & EMERGENCIES
No report No data No data IMMUNIZATION VACCINES & EMERGENCIES ROUTINE IMMUNIZATION PERFORMANCE IN THE AFRICAN REGION October 2013 issue Number of children vaccinated with the 3 rd dose of DTPcontaining
More informationChildren in Africa. Key statistics on child survival, protection and development
Children in Key statistics on child survival, protection and development Key Statistics In, mortality rates among children under five decreased by 48 per cent between 199 and 13, but still half of the
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationAchieving the 3 rd 90 in PEPFAR-supported countries:
Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention
More informationPneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division Update: October 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Outlook October 2013 Update Key updates
More informationApplication for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion...
More informationARV Market Report. The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries. ISSUE 4, November 2013
ARV Market Report The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries ISSUE 4, November 213 ARV Market Report Clinton Health Access Initiative 1 Table of Contents TABLE OF EXHIBITS...
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationIMMUNIZATION & VACCINE PREVENTABLE DISEASES
IMMUNIZATION & VACCINE PREVENTABLE DISEASES MONTHLY IMMUNIZATION UPDATE IN THE AFRICAN REGION July-August 2015 (Vol 3, issue N 6 ) Special issue on WHO/UNICEF Estimates of National Immunization Coverage
More informationDiagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
More informationGABON. Neglected tropical disease treatment report profile for mass treatment of NTDs
GABON Neglected tropical disease treatment report 2017 1 2017 profile for mass treatment of NTDs NEGLECTED TROPICAL DISEASES Neglected tropical diseases (NTDs) are a group of preventable and treatable
More informationWhat is this document and who is it for?
Measles and Rubella Initiative s Standard Operating Procedures for Accessing Support for Measles and Rubella Supplementary Immunization Activities During 2016 In the context of measles and rubella elimination
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationDr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018 1 Number of young people living with HIV (aged 15 19 years) by mode of HIV acquisition, 25 countries,*
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationTHE CARE WE PROMISE FACTS AND FIGURES 2017
THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationExcellence and Originality from Necessity: Palliative Care in Africa. Dr Emmanuel Luyirika Executive Director, African Palliative Care Association
Excellence and Originality from Necessity: Palliative Care in Africa Dr Emmanuel Luyirika Executive Director, African Palliative Care Association Summary of the presentation 1. Introduction 2. Background
More informationPresentation by Dr Philippe Douste-Blazy. Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development
Presentation by Dr Philippe Douste-Blazy Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development The Millennium Goals : Hope for Humanity 2000 UN Millennium Summit
More informationUpdate from GAVI Aurelia Nguyen
Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationFighting Harder and Smarter Against Malaria. Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010
Fighting Harder and Smarter Against Malaria Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010 Outline Burden of malaria Global support for rolling back malaria
More informationO c t o b e r 1 0,
STUDENT VOICES FROM THE FIELD: WORLD HEALTH ORGANIZATION GENEVA, SWITZERLAND O c t o b e r 1 0, 2 0 1 6 M o l l y P e z z u l o University at Albany School of Public Health MPH Epidemiology Candidate 17
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationImpact of Pathology Implementation Strategies in Sub Saharan Africa
Impact of Pathology Implementation Strategies in Sub Saharan Africa June 2015 ascp.org PATHOLOGY IN AFRICA Large abdominal wall mass What do you do?? Large lesion non-diagnostic? Have to do additional
More informationCOLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)
COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) Sushila Maharjan Senior Manager, Innovative Finance International Conference on Sustainable Cooling World Bank Washington DC - 29 November 2018 Reach
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationEXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT
UNICEF / Zar Mon Annexes EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT This report includes nine nutrition statistics, as per the 2017 Global Nutrition Report. These
More informationFunding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia
Funding for AIDS: The World Bank s Role Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia Outline New resources needs estimates Bridging the gap Global overview of
More informationGlobal Fund Mid-2013 Results
Global Fund Mid-2013 Results This fact sheet outlines some of the common questions and answers regarding results reported by Global Fund-supported programs, including the principles and approach in determining
More informationGlobal Fund Results Fact Sheet Mid-2011
Global Fund Results Fact Sheet Mid-2011 This fact sheet outlines some of the common questions and answers regarding results reported by Global Fund-supported programs, including the principles and approach
More informationSupporting Sustained Supply through the Coordinated Procurement of ARVs
Supporting Sustained Supply through the Coordinated Procurement of ARVs ARV Procurement Working Group Newsletter April 2018 Introduction Through quarterly order cycles and business calls, the APWG has
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationGlobal Fund ARV Fact Sheet 1 st June, 2009
Global Fund ARV Fact Sheet 1 st June, 2009 This fact sheet outlines the principles and approach in determining the number of people on antiretroviral drugs (ARVs) for HIV/AIDS treatment, with a breakdown
More informationCurrent State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2
Current State of Global HIV Care Continua Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2 1) International Association of Providers of AIDS Care
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationPaediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
More informationJames Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital
James Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital Paediatric HIV Infection Symposium, August 21, 2010, Red Cross Children s Hospital Overview of talk The 2010 paediatric guidelines
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationTreatment Optimisation Community Condultation Feedback. KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016
Treatment Optimisation Community Condultation Feedback KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016 INTRODUCTION A brief history of ART 1987-90s AZT vecomes available ddi/ddc
More informationPROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS
29 June 2009 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-ninth session Kigali, Republic of Rwanda, 31 August 4 September 2009 Provisional agenda item 9.2 PROGRESS REPORT ON CHILD SURVIVAL: A
More informationANTIRETROVIRAL MEDICINES IN LOW-AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL AND REGIONAL DEMAND FOR TECHNICAL REPORT
TECHNICAL REPORT AIDS MEDICINES AND DIAGNOSTICS SERVICE ANTIRETROVIRAL MEDICINES IN LOW-AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL AND REGIONAL DEMAND FOR 2013-2016 MARCH 2014 ANTIRETROVIRAL MEDICINES
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationImmediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)
Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) Roselyne TOBY,MD, ID specialist Infectious Disease Unit/Yaounde Central Hospital
More informationTURNING POINT FOR AFRICA AN HISTORIC OPPORTUNITY TO END AIDS AS A PUBLIC HEALTH THREAT BY 2030 AND LAUNCH A NEW ERA OF SUSTAINABILITY
TURNING POINT FOR AFRICA AN HISTORIC OPPORTUNITY TO END AIDS AS A PUBLIC HEALTH THREAT BY 2030 AND LAUNCH A NEW ERA OF SUSTAINABILITY UNAIDS 2018 II KEY MESSAGES 1 Ending the AIDS epidemic in Africa is
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationTHE DOUBLE DIVIDEND. Presented at 6 th HIV Paediatric Workshop, Melbourne 19 th July 2014
THE DOUBLE DIVIDEND Action to improve survival of HIV exposed infected and uninfected children in the era of emtct and renewed child survival campaigns: Outcome of Harare Think Tank Consultation Presented
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationPOLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12
5 August 9 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-ninth session Kigali, Republic of Rwanda, August 4 September 9 POLIOMYELITIS ERADICATION: PROGRESS REPORT Information Document CONTENTS
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationCREOLE Study: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans. CREOLE Study
CREOLE Study: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans CREOLE Study BARASA FA. MMED, FIC Cardiologist, MTRH Eldoret Disclosures CREOLE protocol is being funded
More information